Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.
Michael Dennis, MD
Advertisement
Michael Dennis, MD, is a physician at Dana-Farber Cancer Institute; as well as an instructor in medicine at Harvard Medical School
Articles by Michael Dennis, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5